

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP	
2. Address Address1 1800 CONCORD PIKE, P.O. BOX 15437 Address2 _____ City WILMINGTON State DE Zip Code 19850-5437 Country USA	
3. Principal place of business (if different than line 2) City _____ State _____ Zip Code _____ Country _____	
4a. Contact Name Ms. Kate Belinski	b. Telephone Number 2026615599
c. E-mail belinskik@ballardspahr.com	
5. Senate ID# 54073-12	
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP	
6. House ID# 349750000	

TYPE OF REPORT8. Year 2022 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31) 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity **INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13**

12. Lobbying	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSE relating to lobbying activities for this reporting period were:
Less than \$5,000 <input type="checkbox"/>	Less than \$5,000 <input type="checkbox"/>
\$5,000 or more <input type="checkbox"/> \$ _____	\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,480,000.00</u>
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
	<input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only
	<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Digitally Signed By: Kate Belinski

Date

4/20/2022
8:44:07 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 1730/S. 670- Speeding Therapy Access Today Act;
 H.R. 483/S. 350 - Newborn Screening Saves Lives Act;
 H.R. 6000 Cures 2.0 Act;
 H.R. 6584 Diverse and Equitable Participation in Clinical Trials Act;
 S. 2706/H.R. 5030 Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act;
 H.R. 6963 - Accelerated Approval Integrity Act;
 H.R. 6996 – Accelerating Access for Patients Act –
 General issues related to rare disease and orphan drugs;
 Reauthorization of the FDA User Fee Act;
 FDA modernization policy issues;
 Reauthorization of newborn screening programs;
 Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients;
 General issues related to health equity in rare disease and clinical trials;
 General issues related to diagnostics for patients with rare diseases
 Cancer screening, diagnosis & treatment
 Prescription drug electronic labeling
 H.R. 3 – Elijah E. Cummings Lower Drug Costs Now Act;
 H.R. 19 - Lower Costs, More Cures Act;
 H.R. 5260 - Reduced Costs and Continued Cures Act;
 H.R. 5376 - Build Back Better Act
 H.R. 3085/S. 1548 -ENACT Act of 2021
 H.R. 5585 - Advanced Research Project Agency–Health Act
 H.R. 2883, Stop Stalling Access to Affordable Medications
 Issues related to COVID-19 vaccines and therapies;
 Items related to the Administrations Cancer Moonshot
 S. 3799, the PREVENT Pandemics Act
 S. 3509 Creating Efficiency in Foreign Facility Inspections Act
 Prescription Drug User Fee Act (PDUFA)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), White House Office, Office of Science & Technology Policy (OSTP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 3 – Elijah E. Cummings Lower Drug Costs Now Act;
 H.R. 19 - Lower Costs, More Cures Act;
 H.R. 5260 - Reduced Costs and Continued Cures Act;
 H.R. 5376 - Build Back Better Act –
 General issues related to patient access to rare disease therapies, Part B and Part D drugs; Issues related to home infusion for Part B patients;
 Center for Medicare and Medicaid Innovation (CMMI) policy issues;
 Value-based payment arrangements;
 Efforts to improve coding, coverage, and access for rare disease therapies;
 Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; General issues related to diagnostic reimbursement
 S. 1873/H.R. 1946 - Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to the 340B drug discount program.
Discussions related to an appropriations hold on funding for a 2014 FDA rule that would move package inserts (PI) from paper to digital form–e-labeling.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
 H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act.
 H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act.
 H.R. 2891 Preserve Access to Affordable Generics and Biosimilars Act
 H.R. 4521 America COMPETES Act of 2022

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Susie	Ahn			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R. 2623 – Cameron’s Law;
 H.R. 5376 - Build Back Better Act;
 Issues related to the Orphan Drug Tax Credit;
 Issues related to the deduction of research and development expenditures
 Issues related to corporate and international tax reform

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Susie	Ahn			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Issues related to an appropriations hold on funding for a 2014 FDA rule that would provide electronic flexibilities related to package inserts (PI); Appropriations, FY 2022 and FY 2023;
 H.R. 2471, Consolidated Appropriations Act, 2022
 H.R. 2471; Public Service Retirement Fairness Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform
• S. 1435, the Affordable Prescriptions for Patients Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1	_____	_____	3	_____	_____
2	_____	_____	4	_____	_____

ISSUE UPDATE

24. General lobbying issue that no longer pertains

--	--	--	--	--	--	--	--	--

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address City	State/Province	Zip	Country	City State	Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1	2	3
---	---	---

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address City	State/Province	Country			
				City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1	3	5
2	4	6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------